Tobacco Manufacturing (United States) — NAICS 3122

A Histometrics rollup primer for public-market and private investors.

This is a single-child rollup. NAICS (North American Industry Classification System) industry group 3122 contains exactly one industry, 31223 — Tobacco Manufacturing, which in turn holds a single national industry, 312230. So this four-digit level, its five-digit child and the six-digit leaf are effectively the same thing. This page gives the rollup figures and the big picture; for full detail — economics, company-by-company universe, regulation and outlook — see the 31223 primer.

1. Overview

Tobacco manufacturing is the business of turning cured tobacco leaf into finished consumer products — cigarettes, cigars, chewing tobacco, snuff and pipe tobacco — plus the leaf-processing (stemming and redrying) step that feeds those factories.[1] It is one of the most unusual corners of the U.S. economy: a shrinking customer base and a heavily taxed, heavily litigated product, yet extraordinary profitability and cash generation, because nicotine addiction gives makers durable pricing power.[2][3]

For an investor the appeal is simple: this is a classic "cash cow" sector. Owners make money less by selling more units — cigarette volumes fall high-single-digits every year — and more by raising prices faster than volumes decline, then returning the cash as dividends and buybacks. The forward question is whether smoke-free products (nicotine pouches, heated tobacco, vapes) can grow fast enough to replace the fading combustible cigarette business.[2][3]

2. What's inside — and why this level equals its one child

At the four-digit level, NAICS 3122 rolls up a single five-digit industry, which itself rolls up a single six-digit national industry:

Because the chain has no branches, the 3122 group, the 31223 industry and the 312230 leaf are numerically identical — same establishments, same employment, same receipts. (In the 2017/2022 NAICS revisions, cigarettes and "other tobacco" were merged into this one code.[1]) This page therefore stays at the big-picture level and hands off detail to the child primer.

One boundary is worth flagging even here, because it shapes how to read the numbers: several fast-growing pieces of the nicotine economy sit outside this code. Tobacco farming is NAICS 111910; leaf wholesalers are 424940 / 425120; electronic cigarettes / vape devices are NAICS 339999 and e-liquid is 325998 — none are in 312230.[1] So "tobacco manufacturing" statistics increasingly understate where nicotine demand is heading.

3. Size of this level

Ground-truth U.S. federal figures for NAICS 3122 (identical to 31223 / 312230, since it is the sole child chain):

The two output measures are different vintages and different concepts — 2022 Economic Census receipts versus a 2025 Bureau of Labor Statistics sectoral-output series — so treat them as bounds on the size of the level rather than as a contradiction.[3][4]

The standout is productivity: roughly $4.5 million of shipments per worker (2022 receipts over 2023 employment) — among the highest of any U.S. manufacturing industry, reflecting heavy automation, brand pricing and the tax-inflated value of each unit.[2][3]

Two caveats on what these figures capture. First, this is a case where individual/small-owner undercount is not the main issue — the industry is dominated by a few large corporations, so the establishment and firm counts are fairly complete. The distortion runs the other way: (1) the ~$51 billion is what manufacturers collect at the factory gate, well below what consumers spend, since excise tax and retail margin sit on top (federal plus average state cigarette tax alone runs about $2.97 per pack)[5]; and (2) the broader "American tobacco" footprint is larger than the code — Marlboro's international volumes are made abroad, and the surging vape/pouch categories partly fall outside 312230.

Federal concentration data confirm a near-oligopoly: the top 4 firms account for 90.6% of receipts, the top 8 for 95.6%, the top 20 for 98.7%, and the top 50 for 99.8%.[3] (The Herfindahl-Hirschman Index — a standard concentration measure — is suppressed in the federal data for this industry, so we do not report a value.[3])

4. Investable universe — where the value sits

Because the whole chain has one child, all of the industry's investable value lives in 312230, and — unusually for a Histometrics primer — almost the whole industry is reachable through public equities. Value concentrates in a few large brand owners: a U.S. pure-play (Altria, MO, ~$23.5 billion of 2025 net revenue), a global smoke-free growth story (Philip Morris International, PM), and the foreign parents of U.S. businesses (British American Tobacco, BTI, which owns Reynolds American; Imperial Brands, IMB, which owns ITG Brands; and Japan Tobacco, which took Liggett/Vector Group private in October 2024). Smaller listed plays include a niche brand house (Turning Point Brands, TPB) and the leaf-supply chain (Universal Corporation, UVV).[6][7][8][9][10][11][12] Note for fund investors: many ESG-screened funds (screened for environmental, social and governance criteria) exclude tobacco, so exposure usually comes through broad consumer-staples funds rather than a dedicated tobacco ETF (exchange-traded fund). See the 31223 primer for the full company-by-company table.

5. How the money works

The economics are the child's, so only the essentials here. The core model is price over volume: U.S. cigarette pack sales fell about 9.2% in 2024 (to ~6.9 billion packs) and another ~8.2% in 2025, but manufacturers raise net prices faster than volumes fall, so revenue and profit hold or grow.[13] The margin arithmetic that results is the reason the sector exists in an investor's portfolio: Altria's smokeable segment produced $17.4 billion of net revenue and $11.0 billion of operating income in 2025 — a 63% operating margin — even as sticks shipped kept declining.[6] Cigarettes are cheap to make and highly automated — the value is in the brand and the addiction, not the factory — so margins are fat and free cash flow is strong with little reinvestment, funding high dividends and buybacks.[6] Excise taxes and 1998 Master Settlement Agreement payments act like per-pack costs that makers largely pass through in price.[5][14] The new growth engine is smoke-free — nicotine pouches (the fastest-growing category, led by Zyn), heated tobacco and vapes — the bet being that these replace combustible profit as it erodes; PMI shipped 797.9 million nicotine-pouch cans in the Americas in 2025, growth driven predominantly by Zyn in the United States.[15][16][17] Leaf processing (Universal) is a thinner, more commodity-like model.[12] Full detail in the 31223 primer.

6. Demand drivers

• Long-run decline in smoking — the adult cigarette smoking rate hit a record-low 9.1% in 2025 (about 24 million adults), down from 9.9% in 2024 and 42.4% at the 1965 peak; this secular decline is the single biggest force on the industry.[18]

• Addiction and inelastic demand — remaining smokers are relatively price-insensitive, which sustains price-led revenue despite falling volumes.[6]

• Substitution across nicotine formats — consumers migrate from cigarettes to pouches, vapes and heated tobacco, reshuffling where the profit sits rather than eliminating nicotine demand; adult e-cigarette use was 6.7% in 2025.[15][18]

• Taxes and price — higher excise taxes cut volumes and push some buyers toward cheaper or illicit products.[5]

• Demographics, income and down-trading — smoking skews lower-income and older; the discount segment reached 31.8% of measured cigarette retail volume in 2025, up 2.2 percentage points, driven by discretionary-income pressure.[6]

• Youth and new-user dynamics — flavored disposable vapes have drawn younger users, a demand and regulatory flashpoint.[19]

7. Regulation

Tobacco is among the most heavily regulated U.S. consumer industries, and the rules apply identically across this single-child level. The pillars (detailed in the 31223 primer): the U.S. Food and Drug Administration's (FDA) Center for Tobacco Products authorizes new products via the Premarket Tobacco Product Application (PMTA) process, with average review times stretching toward ~700 days[20]; the FDA granted first-of-its-kind reduced-risk marketing to 20 Zyn pouch products in January 2025[21]; the Biden-era menthol-cigarette ban was proposed but never finalized, and was withdrawn in early 2025, while a proposed cap on cigarette nicotine remains the biggest open question for combustibles[22][23]; federal excise tax is $1.01/pack on top of state taxes averaging ~$1.96[5]; and the 1998 Master Settlement Agreement adds perpetual per-pack payments to the states.[14] An enforcement gap on illicit imported flavored vapes rounds out the picture.[19]

8. Consolidation

This is a textbook concentrated market — federal data put the top-4 share of receipts at 90.6%.[3] In cigarettes specifically the skew is sharper still: Altria reported 45.2% of measured U.S. cigarette retail volume in 2025, including 40.5% for Marlboro alone.[6] Decades of dealmaking produced today's structure: British American Tobacco bought Reynolds American outright in 2017 (~$49 billion); Philip Morris International acquired Swedish Match (Zyn) in 2022, pivoting toward smoke-free; and Japan Tobacco bought Vector Group/Liggett in a ~$2.4 billion deal completed October 7, 2024, taking the #4 U.S. player private.[7][8][10] The competitive battleground has shifted from cigarette share to nicotine pouches and heated tobacco.[15][16][21]

9. Risks

• Structural volume decline — cigarette volumes fall ~8–10% a year; the cash-cow model breaks if pricing power ever fails to offset that.[6][13]

• Regulation — a revived nicotine-reduction cap, new flavor bans, or steep excise increases could sharply cut volumes or profitability.[22][23]

• Illicit competition — unauthorized Chinese disposable vapes (est. $2.4+ billion of U.S. sales in 2024, roughly 35% of convenience-store e-cigarette sales) undercut legal products.[19]

• Litigation and settlement drag — ongoing Master Settlement payments and product-liability exposure are permanent costs.[14]

• Smoke-free execution risk — new categories can disappoint (e.g., Altria's ~$2.2 billion NJOY impairment).[24]

• Down-trading — in weak economies smokers shift to discount brands, pressuring premium mix; discount reached 31.8% of measured retail volume in 2025.[6]

• ESG exclusion — many institutional funds cannot own tobacco, structurally capping the buyer base and valuation multiples.

10. How to invest and outlook

Since 3122 is entirely 312230, the routes in are the child's routes. For income / U.S. pure play, Altria (MO); for smoke-free growth, Philip Morris International (PM); for U.S. exposure via a parent, British American Tobacco (BTI) or Imperial Brands (IMB); plus niche small-cap Turning Point Brands (TPB) and supply-chain Universal Corporation (UVV).[6][7][8][9][11][12] There is no dominant U.S.-tobacco ETF; broad consumer-staples funds hold MO/PM while ESG funds exclude the sector. Private routes cluster at the edges the public multinationals don't own — leaf growing and processing, cigars, contract manufacturing, distribution and convenience retail, and independent pouch/vape startups (which sit in adjacent NAICS codes and face the PMTA gauntlet).

The reasoned base case: combustible cigarettes keep shrinking while manufacturers defend cash flows through price, and the next decade's winners are whoever best converts that declining combustible profit pool into leadership in pouches and other reduced-risk nicotine products. It is a high-cash, high-yield sector for income investors who can accept secular decline, regulatory overhang and ESG exclusion — with the smoke-free transition as the swing factor. For the full company-by-company breakdown and detailed analysis, read the 31223 primer.

---

Sources

1. U.S. Census Bureau. "NAICS Code 312230 — Tobacco Manufacturing (2022 definition and exclusions)." 2022. https://www.census.gov/naics/?details=312230&input=312230&year=2022
2. U.S. Census Bureau. "County Business Patterns, NAICS 312230." 2023. (Establishments, employment, payroll — Histometrics ingested federal data.) https://www.census.gov/programs-surveys/cbp.html
3. U.S. Census Bureau. "Economic Census — Concentration Ratios and Receipts, NAICS 312230." 2022. (Firms, receipts, CR4/CR8/CR20/CR50; HHI suppressed.) https://www.census.gov/programs-surveys/economic-census.html
4. Bureau of Labor Statistics. "Industry Productivity: Sectoral Output, NAICS 312230." 2025. https://fred.stlouisfed.org/series/IPUEN312230T300000000
5. Centers for Disease Control and Prevention. "STATE System Excise Tax Fact Sheet" (federal $1.01/pack; average state $1.96/pack). 2024. https://www.cdc.gov/statesystem/factsheets/excisetax/ExciseTax.html
6. Altria Group, Inc. "Altria Reports 2025 Fourth-Quarter and Full-Year Results." 2026. https://investor.altria.com/press-releases/news-details/2026/Altria-Reports-2025-Fourth-Quarter-and-Full-Year-Results-Provides-2026-Earnings-Guidance/default.aspx
7. Philip Morris International Inc. "Philip Morris International Reports 2024 Fourth-Quarter & Full-Year Results." 2025. https://www.pmi.com/investor-relations/press-releases-and-events/press-releases-overview/press-release-details?newsId=28366
8. Wikipedia / Reynolds American Inc. "Reynolds American." 2024. https://en.wikipedia.org/wiki/Reynolds_American
9. Imperial Brands plc. "U.S. Operations." 2025. https://www.imperialbrandsplc.com/careers/our-locations
10. Japan Tobacco / SEC. "Completion of Vector Group Acquisition." October 2024. https://www.sec.gov/Archives/edgar/data/59440/000110465924106503/tm2425692d1_ex99-a5f.htm
11. Turning Point Brands, Inc. "Turning Point Brands Announces Fourth Quarter and Full Year 2024 Results." 2025. https://www.businesswire.com/news/home/20250306952780/en/Turning-Point-Brands-Announces-Fourth-Quarter-and-Full-Year-2024-Results
12. Universal Corporation. "Universal Corporation Reports Annual Results (FY2024, ~$2.7B revenue)." 2024. https://www.prnewswire.com/news-releases/universal-corporation-reports-annual-results-302153294.html
13. Tobacco Monitoring / CDC Foundation. "Changes in U.S. and State Cigarette Sales — Annual Data Brief" (6.9B packs in 2024, -9.2%; -8.2% in 2025). 2025. https://tobaccomonitoring.org/wp-content/uploads/2025/03/Annual-Cigarette-Data-Brief-for-Total-US-and-Selected-States-2024.pdf
14. Public Health Law Center. "Master Settlement Agreement" (~$200B+ payments, perpetual annual payments). 2024. https://www.publichealthlawcenter.org/topics/commercial-tobacco-control/master-settlement-agreement
15. GlobeNewswire / Research and Markets. "United States Nicotine Pouches Market Forecast Report 2025-2033" (~$4B in 2024, ~30%+ CAGR). 2025. https://www.globenewswire.com/news-release/2025/04/21/3064762/0/en/United-States-Nicotine-Pouches-Market-Forecast-Report-2025-2033.html
16. Tobacco Insider. "USA: ZYN Pouches" (~74% share). 2025. https://tobaccoinsider.com/zyn-pouches/
17. Philip Morris International Inc. "PMI 2025 Annual Report" (930.2M cans Americas oral, 797.9M nicotine-pouch cans). 2026. https://www.sec.gov/Archives/edgar/data/0001413329/000162828026021174/pmi_2025xannualreport.pdf
18. Centers for Disease Control and Prevention / NCHS. "FastStats — Smoking" (9.1% adult smoking, 6.7% e-cigarette use in 2025). 2026. https://www.cdc.gov/nchs/fastats/smoking.htm
19. Reuters via AOL / U.S. GAO. "Illegal U.S. vape sales worth at least $2.4 billion in 2024." 2025. https://www.aol.com/news/illegal-u-vape-sales-worth-103028304.html
20. Tobacco Insider / FDA. "The US FDA: PMTA" (premarket review timelines). 2025. https://tobaccoinsider.com/the-us-fda-pmta/
21. U.S. Food and Drug Administration. "FDA Authorizes Marketing of 20 ZYN Nicotine Pouch Products." January 2025. https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-20-zyn-nicotine-pouch-products-after-extensive-scientific-review
22. Network for Public Health Law. "Three Federal Tobacco Regulatory Measures Up for Change in 2025" (menthol ban withdrawal; nicotine-reduction proposal). 2025. https://www.networkforphl.org/news-insights/three-federal-tobacco-regulatory-measures-up-for-change-in-2025/
23. U.S. Food and Drug Administration. "Tobacco Product Standards." 2025. https://www.fda.gov/tobacco-products/products-guidance-regulations/tobacco-product-standards
24. Sure Dividend. "Dividend Kings In Focus: Altria Group" (dividend streak, yield, NJOY impairment). 2025. https://www.suredividend.com/dividend-kings-mo/